Borenius successfully adviced Hospira in a complex patent litigation case before the district court

We successfully advised and represented Hospira, the world’s leading provider of injectable drugs and infusion technologies, in a complex patent litigation case, regarding medicine docetaxel with a commercial value of several millions of Euros. The district court revoked the adverse party’s patent-in-suit and confirmed non-infringement of Hospira’s product. The case is final.